A minimally invasive approach to lung volume reduction.
Endobronchial valve (EBV) therapy based on Chartis treatment planning is an effective, minimally invasive method developed by Pulmonx to manage hyperinflation.1 It is intended to predict and achieve reduction of volume in the diseased portion of the lung, without the risks and complications of surgery. EBV therapy involves an assessment of the patient’s hyperinflated lobes for the presence of collateral ventilation, or airflow within or between lobes of the lung, and then treating the patient by placing small, one-way valves in the targeted airways to direct the flow of air out of diseased portions of the lung. A typical procedure involves a Chartis assessment which typically takes about 5 minutes per lobe, and then placing three to four valves in the target lobe, which takes approximately 10 to 30 minutes to complete.
| How it works: | |
| Diseased lung regions over-inflate, making breathing difficult. |
Zephyr® EBV is deployed in airway using a flexible delivery catheter. |
| One-way valve is designed to block inspired air while allowing trapped air and fluid to escape |
Volume of targeted portion of lung is reduced, allowing healthier regions to function more normally. |
Footnotes
1. Use of Chartis® Pulmonary Assessment System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR) Chartis Multi-Centre Study, data presented at ATS2011. Data on file with Pulmonx.
Zephyr® EBV is an Investigational Device in the United States. Limited by U.S. law to investigational use. Chartis® system is for use/sale outside the U.S. only.
